BioSig Technologies Inc, which is commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, has announced the appointment of Dr James Barry as an independent board director.
The company said Dr Barry has more than 30 years of experience in the medical device industry as an executive and corporate board director. He is currently the Principal Owner at Convergent Biomedical Group LLC., a company providing advisory services to the life sciences industry.
Prior to Convergent, he was president and CEO at InspireMD (NYSE:NSPR) Inc and platform technology company, Arsenal Medical.
READ: BioSig to install PURE EP System for evaluation at St. Elizabeth’s Medical Center in Boston
Dr Barry spent the majority of his career at Boston Scientific (NYSE:BSX), with increasing roles of responsibility culminating as senior vice president of corporate technology. While at Boston Scientific (NYSE:BSX), he led the development and launch of the TAXUS drug-eluting coronary stent that achieved annual sales exceeding $3 billion.
“I have always viewed the electrophysiology field as a tremendous opportunity given the burden heart rhythm disorders have on the healthcare system,” Dr Barry said in a statement. “It is a space that can benefit greatly from innovation, and I am impressed with the PURE EP system which appears to be a meaningful advance in signal detection and should have a positive impact on procedure time and cost. I look forward to working with the BioSig Board and the management team to leverage my experience and executive leadership to deliver on the strategic expansion of the PURE EP(tm) system and the company’s many pipeline opportunities.”
BioSig CEO Kenneth Londoner added: “Jim’s accomplishments in the medical device sector are second-to-none, and we are thrilled that he can join us as our new Independent Director. Our mission is to empower physicians to make better procedural decisions through more advanced technological solutions, and Jim’s industry expertise is perfectly aligned with our passion for innovation. We look forward to learning from Jim as we continue to expand our commercial roll-out.”
The PURE EP is an FDA 510(k) cleared non-invasive class II device that aims to drive procedural efficiency and efficacy in cardiac electrophysiology. To date, over 60 physicians have completed over 1,300 patient cases with the PURE EP System across 12 clinical sites.
The company recently completed its first multi-centered, prospective clinical trial and presented preliminary clinical data during the annual Heart Rhythm 2021 convention in July in Boston.
BioSig is in a focused commercial launch of the PURE EP System in the Northeast, Texas, and Florida and is in regular use in some of the country’s leading centers of excellence, including the Mayo Clinic in Rochester, Minnesota, and St. David’s Medical Center in Austin, Texas.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham